ArticleJournal of personalized medicine2017
Clinical Pharmacogenetics of Cytochrome P450-Associated Drugs in Children.
Article in Journal of personalized medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- A systematic review of real-world evidence on the clinical relevance, characterization, and utility ofJournal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques · 2025Pooled it
- Novel Implementation of Genotype-Guided Proton Pump Inhibitor Medication Therapy in Children: A Pilot, Randomized, Multisite Pragmatic Trial.Clinical and translational science · 2019Trial
- National genomic projects in Asia and Africa: a review.Human genomics · 2026Review
- Pharmacogenomics and Epigenetic Regulation Transforming Pediatric Precision Therapeutics.Journal of personalized medicine · 2026Review
- Personalized Perioperative Opioid Strategies in Children: Focus on Methadone, Pharmacogenomics and Prevention of Persistent Postoperative Opioid Use.Children (Basel, Switzerland) · 2025Review
- ADME related patterns to predict the prognosis and immune therapy of colon cancer patients.Scientific reports · 2025Article
- Review
- Utilisation of drugs with pharmacogenetic recommendations in children in Switzerland.The pharmacogenomics journal · 2025Article
- Co-Occurring Methylenetetrahydrofolate Reductase (Brain sciences · 2024Article
- Pediatric CYP2D6 metabolizer status and post-tonsillectomy nausea and vomiting after ondansetron.Clinical and translational science · 2023Article
- Pharmacogenetic and clinical predictors of ondansetron failure in a diverse pediatric oncology population.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Article
- Influence of CYP2D6 metabolizer status on ondansetron efficacy in pediatric patients undergoing hematopoietic stem cell transplantation: A case series.Clinical and translational science · 2022Article
- Perspectives from the Society for Pediatric Research: pharmacogenetics for pediatricians.Pediatric research · 2022Review
- Establishment of non-small-cell lung cancer risk prediction model based on prognosis-associated ADME genes.Bioscience reports · 2021Article
- Providers' perspectives on the clinical utility of pharmacogenomic testing in pediatric patients.Pharmacogenomics · 2021Article
- Multi-factorial pharmacokinetic interactions: unraveling complexities in precision drug therapy.Expert opinion on drug metabolism & toxicology · 2021Review
- Retrospective Review of Pharmacogenetic Testing at an Academic Children's Hospital.Clinical and translational science · 2021Article
- The Expression Profiles of ADME Genes in Human Cancers and Their Associations with Clinical Outcomes.Cancers · 2020Article
- Primary Care Prescription Drug Use and Related Actionable Drug-Gene Interactions in the Danish Population.Clinical and translational science · 2020Article
- Gene-Based Dose Optimization in Children.Annual review of pharmacology and toxicology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Cytochrome P450 (CYP) enzymes are commonly involved in drug metabolism, and genetic variation in the genes encoding CYPs are associated with variable drug response. While genotype-guided therapy has been clinically implemented in adults, these associations are less well established for pediatric patients. In order to understand the frequency of pediatric exposures to drugs with known CYP interactions, we compiled all actionable drug-CYP interactions with a high level of evidence using Clinical Pharmacogenomic Implementation Consortium (CPIC) data and surveyed 10 years of electronic health records (EHR) data for the number of children exposed to CYP-associated drugs. Subsequently, we performed a focused literature review for drugs commonly used in pediatrics, defined as more than 5000 pediatric patients exposed in the decade-long EHR cohort. There were 48 drug-CYP interactions with a high level of evidence in the CPIC database. Of those, only 10 drugs were commonly used in children (ondansetron, oxycodone, codeine, omeprazole, lansoprazole, sertraline, amitriptyline, citalopram, escitalopram, and risperidone). For these drugs, reports of the drug-CYP interaction in cohorts including children were sparse. There are adequate data for implementation of genotype-guided therapy for children for three of the 10 commonly used drugs (codeine, omeprazole and lansoprazole). For the majority of commonly used drugs with known CYP interactions, more data are required to support pharmacogenomic implementation in children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.